BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 37460463)

  • 1. Proteogenomics of clear cell renal cell carcinoma response to tyrosine kinase inhibitor.
    Zhang H; Bai L; Wu XQ; Tian X; Feng J; Wu X; Shi GH; Pei X; Lyu J; Yang G; Liu Y; Xu W; Anwaier A; Zhu Y; Cao DL; Xu F; Wang Y; Gan HL; Sun MH; Zhao JY; Qu Y; Ye D; Ding C
    Nat Commun; 2023 Jul; 14(1):4274. PubMed ID: 37460463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overview of Current and Future First-Line Systemic Therapy for Metastatic Clear Cell Renal Cell Carcinoma.
    Gill DM; Hahn AW; Hale P; Maughan BL
    Curr Treat Options Oncol; 2018 Jan; 19(1):6. PubMed ID: 29368125
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epithelial-mesenchymal transition as a mechanism of resistance to tyrosine kinase inhibitors in clear cell renal cell carcinoma.
    Hwang HS; Go H; Park JM; Yoon SY; Lee JL; Jeong SU; Cho YM
    Lab Invest; 2019 May; 99(5):659-670. PubMed ID: 30683903
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential new therapy of Rapalink-1, a new generation mammalian target of rapamycin inhibitor, against sunitinib-resistant renal cell carcinoma.
    Kuroshima K; Yoshino H; Okamura S; Tsuruda M; Osako Y; Sakaguchi T; Sugita S; Tatarano S; Nakagawa M; Enokida H
    Cancer Sci; 2020 May; 111(5):1607-1618. PubMed ID: 32232883
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sunitinib, sorafenib and mTOR inhibitors in renal cancer.
    Radulovic S; Bjelogrlic SK
    J BUON; 2007 Sep; 12 Suppl 1():S151-62. PubMed ID: 17935273
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dyskerin and telomerase RNA component are sex-differentially associated with outcomes and Sunitinib response in patients with clear cell renal cell carcinoma.
    Yuan H; Qin X; Yang Q; Liu L; Fang Z; Fan Y; Xu D
    Biol Sex Differ; 2023 Jul; 14(1):46. PubMed ID: 37434223
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low DAPK1 expression correlates with poor prognosis and sunitinib resistance in clear cell renal cell carcinoma.
    Song Z; Li Z; Han W; Zhu C; Lou N; Li X; Luo G; Peng S; Li G; Zhao Y; Guo Y
    Aging (Albany NY); 2020 Nov; 13(2):1842-1858. PubMed ID: 33201837
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PD-L1 Upregulation by the mTOR Pathway in VEGFR-TKI-Resistant Metastatic Clear Cell Renal Cell Carcinoma.
    Jeong SU; Hwang HS; Park JM; Yoon SY; Shin SJ; Go H; Lee JL; Jeong G; Cho YM
    Cancer Res Treat; 2023 Jan; 55(1):231-244. PubMed ID: 35240013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic significance of VHL, HIF1A, HIF2A, VEGFA and p53 expression in patients with clear‑cell renal cell carcinoma treated with sunitinib as first‑line treatment.
    Wierzbicki PM; Klacz J; Kotulak-Chrzaszcz A; Wronska A; Stanislawowski M; Rybarczyk A; Ludziejewska A; Kmiec Z; Matuszewski M
    Int J Oncol; 2019 Aug; 55(2):371-390. PubMed ID: 31268155
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Significance of tumor microenvironment in acquiring resistance to vascular endothelial growth factor-tyrosine kinase inhibitor and recent advance of systemic treatment of clear cell renal cell carcinoma.
    Mikami S; Mizuno R; Kosaka T; Tanaka N; Kuroda N; Nagashima Y; Okada Y; Oya M
    Pathol Int; 2020 Oct; 70(10):712-723. PubMed ID: 32652869
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Addressing the best treatment for non-clear cell renal cell carcinoma: A meta-analysis of randomised clinical trials comparing VEGFR-TKis versus mTORi-targeted therapies.
    Ciccarese C; Iacovelli R; Brunelli M; Massari F; Bimbatti D; Fantinel E; De Marco V; Porcaro AB; Martignoni G; Artibani W; Tortora G
    Eur J Cancer; 2017 Sep; 83():237-246. PubMed ID: 28756136
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular subtypes of clear cell renal cell carcinoma are associated with sunitinib response in the metastatic setting.
    Beuselinck B; Job S; Becht E; Karadimou A; Verkarre V; Couchy G; Giraldo N; Rioux-Leclercq N; Molinié V; Sibony M; Elaidi R; Teghom C; Patard JJ; Méjean A; Fridman WH; Sautès-Fridman C; de Reyniès A; Oudard S; Zucman-Rossi J
    Clin Cancer Res; 2015 Mar; 21(6):1329-39. PubMed ID: 25583177
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Y-box binding protein-1 is crucial in acquired drug resistance development in metastatic clear-cell renal cell carcinoma.
    D'Costa NM; Lowerison MR; Raven PA; Tan Z; Roberts ME; Shrestha R; Urban MW; Monjaras-Avila CU; Oo HZ; Hurtado-Coll A; Chavez-Munoz C; So AI
    J Exp Clin Cancer Res; 2020 Feb; 39(1):33. PubMed ID: 32041631
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ZDHHC2-Mediated AGK Palmitoylation Activates AKT-mTOR Signaling to Reduce Sunitinib Sensitivity in Renal Cell Carcinoma.
    Sun Y; Zhu L; Liu P; Zhang H; Guo F; Jin X
    Cancer Res; 2023 Jun; 83(12):2034-2051. PubMed ID: 37078777
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Carbonic anhydrase 9 expression increases with vascular endothelial growth factor-targeted therapy and is predictive of outcome in metastatic clear cell renal cancer.
    Stewart GD; O'Mahony FC; Laird A; Rashid S; Martin SA; Eory L; Lubbock AL; Nanda J; O'Donnell M; Mackay A; Mullen P; McNeill SA; Riddick AC; Aitchison M; Berney D; Bex A; Overton IM; Harrison DJ; Powles T
    Eur Urol; 2014 Nov; 66(5):956-63. PubMed ID: 24821582
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reversible epithelial to mesenchymal transition and acquired resistance to sunitinib in patients with renal cell carcinoma: evidence from a xenograft study.
    Hammers HJ; Verheul HM; Salumbides B; Sharma R; Rudek M; Jaspers J; Shah P; Ellis L; Shen L; Paesante S; Dykema K; Furge K; Teh BT; Netto G; Pili R
    Mol Cancer Ther; 2010 Jun; 9(6):1525-35. PubMed ID: 20501804
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CircPTEN suppresses human clear cell renal carcinoma progression and resistance to mTOR inhibitors by targeting epigenetic modification.
    Zhan Y; Liu Y; Yang R; Chen Q; Teng F; Huang Y; Jiang X; Wang Y; Yu B; Zhang D; Bao L; Liu X; Huang J
    Drug Resist Updat; 2023 Nov; 71():101003. PubMed ID: 37866104
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors.
    Shah AY; Kotecha RR; Lemke EA; Chandramohan A; Chaim JL; Msaouel P; Xiao L; Gao J; Campbell MT; Zurita AJ; Wang J; Corn PG; Jonasch E; Motzer RJ; Sharma P; Voss MH; Tannir NM
    Eur J Cancer; 2019 Jun; 114():67-75. PubMed ID: 31075726
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical evidence that MNK/eIF4E inhibition by cercosporamide enhances the response to antiangiogenic TKI and mTOR inhibitor in renal cell carcinoma.
    Chen S; Cui L; Hu Q; Shen Y; Jiang Y; Zhao J
    Biochem Biophys Res Commun; 2020 Sep; 530(1):142-148. PubMed ID: 32828276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of Efficacy and Toxicity Profile of First-Line Sunitinib or Pazopanib in Metastatic Clear Cell Renal Cell Carcinoma in the Brazilian Population.
    Isaacsson Velho P; Nardo M; Souza MCLA; Bonadio RRCC; Marta GN; Muniz DQB; Bastos DA; Dzik C
    J Glob Oncol; 2018 Aug; 4():1-10. PubMed ID: 30199304
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.